Developer docs
API playgroundTry for free, no card

Search company profiles

Oligomerix

Full company profile

uuid0000u54

Namestring
Oligomerix
Legal namestring
Oligomerix, Inc.
Websiteurl
oligomerix.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Oligomerix, Inc. is a privately held clinical-stage biotechnology company founded in 2006 and headquartered at the Albert Einstein College of Medicine campus in the Bronx, New York. The company is singularly focused on developing oral, disease-modifying small molecule therapeutics that inhibit tau protein self-association—the earliest step in the tau aggregation cascade implicated in Alzheimer's disease and related tauopathies. Its lead clinical asset, OLX-07010, is an oral small molecule that has completed Phase 1a testing (May 2026) with a favorable safety profile and is being progressed toward Phase 1b studies in patients; a second-generation series of tau aggregation inhibitors and a companion biomarker program extend the pipeline. Proprietary technology is centered on a screening platform using full-length tau under conditions promoting oligomer formation without aggregation enhancers or intercalating dyes, protected by an issued patent estate spanning composition-of-matter, methods-of-use, and antibody reagent claims in the US and internationally.

Oligomerix serves patients with Alzheimer's disease (addressable population of 6.7 million in the US, projected to reach 12.7 million by 2050) and rare tauopathies including progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS). The company has no commercialized products and does not generate product revenue; its intended go-to-market is to advance OLX-07010 through early-stage clinical development in-house and then partner with larger pharmaceutical companies for late-stage development, global manufacturing, and commercialization. The June 2026 exclusive worldwide licensing agreement with NanoDetection Technology for a portfolio of nine Tau diagnostic antibodies extends the franchise into companion diagnostics. To date, the company has been funded primarily through non-dilutive NIH/NIA SBIR and related grants (cumulatively over $15 million) and modest equity rounds (Series A $2 million in April 2013, Series B extension $2.7 million in June 2022).

Short descriptiontext

Oligomerix is a privately held, clinical-stage biotechnology company developing oral, disease-modifying small molecule inhibitors of tau self-association for Alzheimer's disease and rare neurodegenerative tauopathies such as PSP, FTD, and ALS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBronx, United States
HQ citystring
Bronx
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tau protein aggregation, Alzheimer's disease therapeutics, small molecule inhibitors, neurodegenerative disease treatment, rare tauopathies
Industry1 code
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Neurodegenerative Disease Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue biotech company developing disease-modifying oral small molecule therapeutics for Alzheimer's disease and rare neurodegenerative diseases. Revenue will be generated through eventual product sales following regulatory approval.

oligomerix.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Oligomerix is a clinical-stage biotechnology company that discovers and develops oral, disease-modifying small molecule therapeutics that inhibit tau protein self-association at the beginning of the tau aggregation cascade. Its lead candidate OLX-07010 targets Alzheimer's disease and rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD), supported by a proprietary screening platform, a 2nd generation compound series, a companion biomarker program, and a recently licensed portfolio of diagnostic tau antibodies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1a clinical trial completed in 2025/2026
+2 more records
Product overview1 text field

Oligomerix is a clinical stage biotechnology company pioneering disease-modifying, oral small molecule therapeutics targeting protein aggregation in Alzheimer's disease and rare neurodegenerative diseases. The company's core product is OLX-07010, a small molecule inhibitor of tau self-association currently in Phase 1a clinical trials. The platform includes a 2nd generation series of tau aggregation inhibitors and a companion biomarker program. In June 2026, the company expanded into diagnostics through an exclusive licensing agreement for a portfolio of nine Tau antibodies for neurodegenerative disease diagnostics.

Product and service4 records
1OLX-07010
Categorycore product
Description

Oral, disease-modifying small molecule inhibitor of tau self-association for the treatment of Alzheimer's disease and rare tauopathies including progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). Currently in Phase 1a clinical development with a completed Phase 1a study in May 2026 showing a favorable safety profile.

22nd Generation Tau Aggregation Inhibitor Series
Categorypipeline product
Description

Second generation series of small molecule tau aggregation inhibitors in preclinical development alongside the lead compound OLX-07010.

3Companion Biomarker Program
Categorydiagnostic tool
Description

Biomarker development program companion to the therapeutic platform, supporting drug development and potentially patient selection for clinical trials.

4Tau Antibody Diagnostic Portfolio
Categorydiagnostic product
Description

Portfolio of nine specialized Tau antibodies for detection of specific forms of aggregated Tau to advance diagnostics for Alzheimer's disease and distinguish it from other neurodegenerative conditions including Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1NanoDetection Technology
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-06-12
Description

Exclusive worldwide licensing agreement for a portfolio of nine specialized Tau antibodies designed to advance diagnostics for Alzheimer's disease and related neurodegenerative disorders. The technology enables detection of specific forms of aggregated Tau that may help distinguish Alzheimer's from other conditions including Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration. NanoDetection has integrated the antibodies into its TRACE-Tau platform with clinical validation ongoing through collaborations with UMass Chan Medical School.

longevity.technology
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on in vivo Alzheimer's disease treatment data publication.

3Albert Einstein College of Medicine
Strategic tierMinorTypeStrategic or Co-development Partner
Description

The company relocated to the Albert Einstein College of Medicine campus for research collaboration purposes.

oligomerix.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical validation ongoing through collaborations with UMass Chan Medical School for diagnostic antibody technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage biotech developing therapeutics for neurodegeneration and lysosomal storage diseases, including small molecule approaches to tau and other CNS targets. Comparable as a CNS-focused biotech, though broader in scope.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics against misfolded proteins including tau and amyloid for Alzheimer's and rare neurodegenerative diseases. Directly comparable in target class, indication focus, and small-molecule/biologic modality mix.

TypeBroad incumbent
Description

Large biopharmaceutical company with the leading approved disease-modifying Alzheimer's franchise (Leqembi, with Eisai) and a broad neuroscience pipeline. Sets the competitive bar Oligomerix must clear in AD.

TypeEmerging player
Description

Clinical-stage CNS biopharma developing therapeutics for neurological disorders including Alzheimer's agitation. Comparable as a small-cap neuroscience-focused developer, though Sage's focus is broader.

TypeDirect peer
Description

Clinical-stage biotech developing oral small molecule therapeutics for Alzheimer's disease and dementia-related disorders. Comparable in modality (oral small molecule), indication (AD), and clinical-stage positioning.

TypeDirect peer
Description

Swiss clinical-stage biotech developing both therapeutics and diagnostics targeting tau, amyloid, and neuroinflammation for Alzheimer's and related dementias. Closely comparable given shared tau focus and dual therapeutic/diagnostic strategy.

TypeDirect peer
Description

Clinical-stage biotech developing oral small molecule sigma-1 receptor agonists (blarcamesine) for Alzheimer's, Rett syndrome, and other neurodegenerative diseases. Comparable in oral small molecule approach and neurodegenerative indication focus.

8Eisai
TypeBroad incumbent
Description

Japanese pharmaceutical company co-developing Leqembi with Biogen for Alzheimer's and pursuing additional tau-targeting programs. A likely BD/licensing partner and major competitive incumbent in AD.

9Cassava Sciences
TypeDirect peer
Description

Clinical-stage biotech developing oral small molecule therapeutics (simufilam) for Alzheimer's disease. Comparable as a small-molecule AD therapeutics developer at similar clinical stage.

TypeBroad incumbent
Description

Large pharmaceutical company with the approved anti-amyloid Kisunla (donanemab) and a broad neuroscience pipeline including tau and other AD targets. Sets competitive and regulatory benchmarks in AD therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oligomerix

Neurodegenerative Disease Therapeuticsoligomerix.com

Oligomerix is a privately held, clinical-stage biotechnology company developing oral, disease-modifying small molecule inhibitors of tau self-association for Alzheimer's disease and rare neurodegenerative tauopathies such as PSP, FTD, and ALS.

What Oligomerix does

Oligomerix, Inc. is a privately held clinical-stage biotechnology company founded in 2006 and headquartered at the Albert Einstein College of Medicine campus in the Bronx, New York. The company is singularly focused on developing oral, disease-modifying small molecule therapeutics that inhibit tau protein self-association—the earliest step in the tau aggregation cascade implicated in Alzheimer's disease and related tauopathies. Its lead clinical asset, OLX-07010, is an oral small molecule that has completed Phase 1a testing (May 2026) with a favorable safety profile and is being progressed toward Phase 1b studies in patients; a second-generation series of tau aggregation inhibitors and a companion biomarker program extend the pipeline. Proprietary technology is centered on a screening platform using full-length tau under conditions promoting oligomer formation without aggregation enhancers or intercalating dyes, protected by an issued patent estate spanning composition-of-matter, methods-of-use, and antibody reagent claims in the US and internationally.

Oligomerix serves patients with Alzheimer's disease (addressable population of 6.7 million in the US, projected to reach 12.7 million by 2050) and rare tauopathies including progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS). The company has no commercialized products and does not generate product revenue; its intended go-to-market is to advance OLX-07010 through early-stage clinical development in-house and then partner with larger pharmaceutical companies for late-stage development, global manufacturing, and commercialization. The June 2026 exclusive worldwide licensing agreement with NanoDetection Technology for a portfolio of nine Tau diagnostic antibodies extends the franchise into companion diagnostics. To date, the company has been funded primarily through non-dilutive NIH/NIA SBIR and related grants (cumulatively over $15 million) and modest equity rounds (Series A $2 million in April 2013, Series B extension $2.7 million in June 2022).

Oligomerix firmographics

Firmographics
Name
Oligomerix
Legal name
Oligomerix, Inc.
Website
https://oligomerix.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Oligomerix is a privately held, clinical-stage biotechnology company developing oral, disease-modifying small molecule inhibitors of tau self-association for Alzheimer's disease and rare neurodegenerative tauopathies such as PSP, FTD, and ALS.
Ownership category
akta.pro rank

Oligomerix industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Tau protein aggregation
  • Alzheimer's disease therapeutics
  • Small molecule inhibitors
  • Neurodegenerative disease treatment
  • Rare tauopathies

Where Oligomerix is headquartered

Location

Headquarters

HQ city
Bronx
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Oligomerix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Pre-revenue biotech company developing disease-modifying oral small molecule therapeutics for Alzheimer's disease and rare neurodegenerative diseases. Revenue will be generated through eventual product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Oligomerix product offering

Product offering

Core offering

Oligomerix is a clinical-stage biotechnology company that discovers and develops oral, disease-modifying small molecule therapeutics that inhibit tau protein self-association at the beginning of the tau aggregation cascade. Its lead candidate OLX-07010 targets Alzheimer's disease and rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD), supported by a proprietary screening platform, a 2nd generation compound series, a companion biomarker program, and a recently licensed portfolio of diagnostic tau antibodies.

Product overview

Oligomerix is a clinical stage biotechnology company pioneering disease-modifying, oral small molecule therapeutics targeting protein aggregation in Alzheimer's disease and rare neurodegenerative diseases. The company's core product is OLX-07010, a small molecule inhibitor of tau self-association currently in Phase 1a clinical trials. The platform includes a 2nd generation series of tau aggregation inhibitors and a companion biomarker program. In June 2026, the company expanded into diagnostics through an exclusive licensing agreement for a portfolio of nine Tau antibodies for neurodegenerative disease diagnostics.

Differentiator

Problem solved

Functional benefit

Products and services

  • OLX-07010 Oral, disease-modifying small molecule inhibitor of tau self-association for the treatment of Alzheimer's disease and rare tauopathies including progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). Currently in Phase 1a clinical development with a completed Phase 1a study in May 2026 showing a favorable safety profile.
  • 2nd Generation Tau Aggregation Inhibitor Series Second generation series of small molecule tau aggregation inhibitors in preclinical development alongside the lead compound OLX-07010.
  • Companion Biomarker Program Biomarker development program companion to the therapeutic platform, supporting drug development and potentially patient selection for clinical trials.
  • Tau Antibody Diagnostic Portfolio Portfolio of nine specialized Tau antibodies for detection of specific forms of aggregated Tau to advance diagnostics for Alzheimer's disease and distinguish it from other neurodegenerative conditions including Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration.

Quantifiable outcome

  • Phase 1a clinical trial completed in 2025/2026
  • +2 more outcomes

Companies that use Oligomerix

Customer profile

Segments2 records

Ideal customer profiles3 records

Oligomerix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Oligomerix partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • NanoDetection TechnologycoreOEM/ Whitelabel/ Licensing Partner · 12 June 2026Exclusive worldwide licensing agreement for a portfolio of nine specialized Tau antibodies designed to advance diagnostics for Alzheimer's disease and related neurodegenerative disorders. The technology enables detection of specific forms of aggregated Tau that may help distinguish Alzheimer's from other conditions including Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration. NanoDetection has integrated the antibodies into its TRACE-Tau platform with clinical validation ongoing through collaborations with UMass Chan Medical School.
  • Feinstein Institutes for Medical ResearchminorStrategic or Co-development PartnerCollaboration on in vivo Alzheimer's disease treatment data publication.
  • Albert Einstein College of MedicineminorStrategic or Co-development PartnerThe company relocated to the Albert Einstein College of Medicine campus for research collaboration purposes.
  • UMass Chan Medical SchoolminorStrategic or Co-development PartnerClinical validation ongoing through collaborations with UMass Chan Medical School for diagnostic antibody technology.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Oligomerix competitors and assessment

Company assessment

Emerging players

  • Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegeneration and lysosomal storage diseases, including small molecule approaches to tau and other CNS targets. Comparable as a CNS-focused biotech, though broader in scope.
  • Sage Therapeutics: Clinical-stage CNS biopharma developing therapeutics for neurological disorders including Alzheimer's agitation. Comparable as a small-cap neuroscience-focused developer, though Sage's focus is broader.

Direct peers

  • Prothena Corporation: Clinical-stage biotech developing therapeutics against misfolded proteins including tau and amyloid for Alzheimer's and rare neurodegenerative diseases. Directly comparable in target class, indication focus, and small-molecule/biologic modality mix.
  • Cognition Therapeutics: Clinical-stage biotech developing oral small molecule therapeutics for Alzheimer's disease and dementia-related disorders. Comparable in modality (oral small molecule), indication (AD), and clinical-stage positioning.
  • AC Immune SA: Swiss clinical-stage biotech developing both therapeutics and diagnostics targeting tau, amyloid, and neuroinflammation for Alzheimer's and related dementias. Closely comparable given shared tau focus and dual therapeutic/diagnostic strategy.
  • Anavex Life Sciences: Clinical-stage biotech developing oral small molecule sigma-1 receptor agonists (blarcamesine) for Alzheimer's, Rett syndrome, and other neurodegenerative diseases. Comparable in oral small molecule approach and neurodegenerative indication focus.
  • Cassava Sciences: Clinical-stage biotech developing oral small molecule therapeutics (simufilam) for Alzheimer's disease. Comparable as a small-molecule AD therapeutics developer at similar clinical stage.

Broad incumbents

  • Biogen: Large biopharmaceutical company with the leading approved disease-modifying Alzheimer's franchise (Leqembi, with Eisai) and a broad neuroscience pipeline. Sets the competitive bar Oligomerix must clear in AD.
  • Eisai: Japanese pharmaceutical company co-developing Leqembi with Biogen for Alzheimer's and pursuing additional tau-targeting programs. A likely BD/licensing partner and major competitive incumbent in AD.
  • Eli Lilly: Large pharmaceutical company with the approved anti-amyloid Kisunla (donanemab) and a broad neuroscience pipeline including tau and other AD targets. Sets competitive and regulatory benchmarks in AD therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Oligomerix social profiles

Digital presence

Oligomerix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oligomerix leadership team

Management profile

Number of profiles

Profiles14 records

Oligomerix funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oligomerix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oligomerix

What does Oligomerix do?

Oligomerix is a clinical-stage biotechnology company that discovers and develops oral, disease-modifying small molecule therapeutics that inhibit tau protein self-association at the beginning of the tau aggregation cascade. Its lead candidate OLX-07010 targets Alzheimer's disease and rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD), supported by a proprietary screening platform, a 2nd generation compound series, a companion biomarker program, and a recently licensed portfolio of diagnostic tau antibodies.

Is Oligomerix a public or private company?

Oligomerix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oligomerix founded?

Oligomerix was founded in 2006. It employs 11 to 50 people.

Where is Oligomerix based?

Oligomerix is headquartered in Bronx, United States, in the North America region.

How does Oligomerix make money?

One revenue line is on record: drug Development and Commercialization.

Who are Oligomerix's main competitors?

Emerging players on record are Denali Therapeutics and Sage Therapeutics. Direct peers are Prothena Corporation, Cognition Therapeutics, AC Immune SA, Anavex Life Sciences and Cassava Sciences. Broad incumbents are Biogen, Eisai and Eli Lilly.

Does Oligomerix have an API?

No public API is recorded for Oligomerix.

What industry is Oligomerix in?

Oligomerix's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyOligomerix puts tau drug in new hands as trials beginOligomerix appointed Cara Cassino as interim President and CEO, with its tau-targeting drug OLX-07010 clearing its first human safety trial. The company is advancing the oral compound into next clinical stages, targeting Alzheimer's and other tau-related diseases.Longevity.TechnologyOligomerix appoints new interim CEO to advance Alzheimer’s drug pipelineOligomerix appointed Cara Cassino, M.D., as interim president and CEO on 31 August 2026. She brings 25 years of drug development experience and will lead the company's transition to a clinical-stage drug developer. The company is advancing its lead Alzheimer's candidate OLX 07010 after a Phase 1a study.Longevity.TechnologyOligomerix appoints new interim CEO to lead Alzheimer’s drug developmentOligomerix appointed Dr. Cara Cassino as interim president and CEO to lead Alzheimer's drug development. The company's lead candidate OLX-07010 completed a Phase 1a study with a favorable safety profile, and the company is preparing to advance it into further clinical testing.Longevity.TechnologyCan a pill succeed where Alzheimer’s drugs struggle?New York-based biotech Oligomerix has received a $1.9 million Phase II Fast-Track grant from the National Institute on Aging, part of the NIH, to fund safety studies for OLX-07010, an experimental oral therapy for Alzheimer's disease targeting tau protein. The funding will support a 13-week toxicology study required before launching a planned Phase 1b clinical trial in Alzheimer's patients, building on prior Phase 1a testing in healthy volunteers. The company positions the oral small-molecule drug as a potentially more accessible alternative to existing antibody-based therapies that require intravenous infusions or injections.Longevity.TechnologyOligomerix wins $1.9m NIH grant to advance Alzheimer’s drug safety trialsOligomerix has received a $1.9 million Phase II Small Business Innovation Research Fast-Track grant from the National Institute on Aging, part of the NIH, to fund nonclinical safety studies for OLX-07010, an oral small molecule drug targeting pathological tau aggregates in Alzheimer's disease. The grant will support a 13-week dosing study in a non-rodent species to complement completed rodent work and enable a same-duration safety study in human Alzheimer's patients as the company progresses toward Phase 1b trials. OLX-07010 has already completed Phase 1a testing, showing a favorable safety profile and the ability to prevent tau accumulation in multiple transgenic animal models.Pulse 2.0Oligomerix Awarded $1.9 Million NIH Grant For Alzheimer’s Disease Safety StudiesOligomerix announced it received a $1.9 million NIH Fast-Track Phase II award from the National Institute on Aging to support clinical development of OLX-07010, an orally administered investigational drug targeting pathological tau aggregates that drive Alzheimer's disease progression. The grant will fund required safety studies for three-month dosing in Alzheimer's patients to support a planned Phase 1b study, following successful completion of Phase 1a human testing and rodent studies. The company noted that currently approved Alzheimer's treatments are antibody-based requiring infusions or injections, creating an unmet need for easier-to-administer disease-modifying oral therapies for the condition affecting over 7.4 million Americans.BioSpaceOligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer’s PatientsOligomerix received a $1.9 million NIH Fast-Track Phase II grant to conduct safety studies for OLX-07010, an oral tau-targeting drug. The 13-week dosing study in a non-rodent species will enable the first safety study in Alzheimer's patients, supporting a planned Phase 1b trial.Business Wire BlogOligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer’s PatientsOligomerix, Inc. has been awarded a $1.9 million Phase II SBIR Fast-Track grant from the National Institutes of Health to conduct safety studies for its investigational drug OLX-07010 in Alzheimer’s patients. This funding supports the development of oral small molecule therapeutics targeting pathological tau aggregates, aiming to provide an alternative to existing antibody-based treatments. The grant facilitates critical preclinical work required to advance the planned Phase 1b clinical trial.Longevity.TechnologyExclusive deal expands neurodegenerative diagnosticsNanoDetection Technology and Oligomerix have announced an exclusive worldwide licensing agreement for a portfolio of nine specialized Tau antibodies designed to advance diagnostics for Alzheimer’s disease and related neurodegenerative disorders. The technology enables detection of specific forms of aggregated Tau that may help distinguish Alzheimer’s from other conditions including Frontotemporal Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration, addressing a long-standing diagnostic challenge posed by overlapping symptoms. NanoDetection has already integrated the antibodies into its TRACE-Tau platform, with clinical validation ongoing through collaborations with UMass Chan Medical School.BioSpaceOligomerix Completes Ph 1a Clinical Study on OLX-07010Oligomerix completed Phase 1a of its OLX-07010 study in 76 healthy volunteers, reporting favorable safety and pharmacokinetics. The tau-self association inhibitor reached serum levels associated with efficacy in animal models. The company plans to present full results at an upcoming scientific meeting and advance to Phase 1b.